Sign Up to like & get
recommendations!
0
Published in 2017 at "Psychopharmacology"
DOI: 10.1007/s00213-017-4664-z
Abstract: AimIt is widely assumed that the upcoming therapeutics for Alzheimer’s disease will require to act on more than one target to be effective. We investigated here whether a combination of the nicotinic receptor allosteric modulator/cholinesterase…
read more here.
Keywords:
allosteric modulator;
nicotinic receptor;
galantamine;
effect ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Australasian Journal of Dermatology"
DOI: 10.1111/ajd.13356
Abstract: Eighty consecutive Chinese patients diagnosed with Alzheimer disease were assessed for darkening of grey hair. Of the 62 eligible patients (mean age = 79.3 ± 7.9 years; male: female = 1:1.48), 24/62 (38.7%, 95%CI: 26.6…
read more here.
Keywords:
cholinesterase inhibitor;
hair;
hair darkening;
pigmentation hair ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Journal of the American Geriatrics Society"
DOI: 10.1111/jgs.15442
Abstract: To examine dose‐related prescribing and short‐term serious events associated with initiation of cholinesterase inhibitor (ChEI) therapy.
read more here.
Keywords:
therapy;
initial cholinesterase;
cholinesterase inhibitor;
serious events ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Current Alzheimer research"
DOI: 10.2174/1567205015666171212105412
Abstract: BACKGROUND 6-chlorotacrine is a cholinesterase inhibitor showing good inhibitory potential, even better than parent compound tacrine, in vitro. Despite tacrine scaffold is broadly used for design and synthesis of novel compounds with anti-Alzheimer's potential, no…
read more here.
Keywords:
biochemistry;
behavioural effects;
chlorotacrine;
compound ... See more keywords